This was the stock's second consecutive day of losses.

In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

In the latest trading session, Eli Lilly (LLY) closed at $852.35, marking a -1.45% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. On the other hand, ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. Lilly makes tirzepatide, commercialized under ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target ...

Eli Lilly (NYSE: LLY) stock defied today's market ... It's as simple as that -- and good enough for a 2.6% stock price bump. Ever feel like you missed the boat in buying the most successful ...

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Lilly is launching two new doses and cutting prices for self-paying customers Eli Lilly & Co. said Tuesday ... alternatives to be made, sending the stock of telehealth provider Hims & Hers Health ...